Quad ties: India targets 1 billion Covid vaccine output by end of 2022 | India News

NEW DELHI: Under ‘Quad Vaccine Cooperation’, India is looking to increase the production of Covid-19 vaccines by around 1 billion doses by the end of next year.
“The discussions among the Quad partners (Australia, India, Japan and the US) as well as their agencies and companies are currently ongoing,” said department of biotechnology (DBT) of science & technology ministry which is closely coordinating with ministry of external affairs (MEA) on strengthening the vaccine manufacturing capacities under the Quad framework.
Asked about the timeline to ramp up vaccine manufacture in the country, the department in its written response said, “The proposal is to increase the production by around 1 billion doses by the end of 2022.”
Responding to TOI’s questions on plans to ramp up vaccine production under the ‘Quad Vaccine Cooperation’, the DBT said, “Considering India’s strengths in vaccine manufacturing, the country has been identified to provide manufacturing support. Quad partners will address financing and logistical demands for production, procurement, and delivery of safe and effective vaccines.”
Under the cooperation to accelerate the global Covid-19 response and to build longer term global health security, the Quad partners will work to use the “shared tools and expertise”, through mechanisms at institutions including the United States Development Finance Corporation (DFC), Japan International Cooperation Agency (JICA), Japan Bank of International Cooperation (JBIC) and others.
“JICA is in discussions with the government of India to provide concessional yen loans to expand manufacturing for Covid-19 vaccines. We are still in the preparation process, and will inform the matter of assisting Indian vaccine manufacturers later,” said Nagai Shinsuke, senior representative, JICA India.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button